Strain-Independent Therapeutic Antibodies for Influenza

描述（由申请人提供）：Trellis Bioscience的CellSpot技术用于鉴定罕见的具有高特异性和亲和力的针对多种抗原的人抗体，已经发现了高效的呼吸道合胞病毒和巨细胞病毒的菌株独立抗体。我们现在已经应用CellSpot分离出两种分别对1组和2组甲型流感毒株具有广泛反应性的天然人抗体。这两种抗体现在已被证明具有体内功效。此外，我们已经分离出一种具有体外抗乙型流感活性的人抗体。我们建议将这些候选治疗方案推进到IND阶段，包括额外的体外中和研究

DESCRIPTION (provided by applicant): Trellis Bioscience's CellSpot" technology for identification of rare human antibodies with high specificity and affinity against multiple antigen has enabled discovery of highly efficacious strain- independent antibodies to Respiratory Syncytial Virus and to Cytomegalovirus. We have now applied CellSpot to isolate two native human antibodies with broad reactivity to Group 1 and Group 2 influenza A strains respectively. Both of these antibodies have now been shown to have in vivo efficacy. In addition, we have isolated a human antibody with in vitro activity against Influenza B. We propose to advance these therapeutic candidates to IND stage, including additional neutralization studies in vitro and in vivo, manufacturing, toxicity, and PK studies. The resulting clinical candidates are expected to provide potent post-infection antiviral activity against all currently circulating strains, and effective prophylaxis against any emerging pandemic strain.